NEW YORK, NY--(Marketwire - Jan 25, 2012) - The medical device sector has been seeing increased investor interest over the last year. According to a recent report from Dow Jones, venture investments held strong across healthcare in 2011, with medical devices finishing a close second to biopharmaceuticals in dollars invested. Biopharmaceuticals brought in $3.9 billion for 302 deals while 290 medical device deals raised $3.3 billion. In the third quarter device deals raised more than drugs for the first time since 1998, CMIO reports. Five Star Equities examines the outlook for companies in the Medical Equipment & Supplies industry and provides equity research on Antares Pharma Inc. (NYSE Amex: [ AIS ]) and Boston Scientific Corporation (NYSE: [ BSX ]). Access to the full company reports can be found at:

[ www.fivestarequities.com/AIS ]
[ www.fivestarequities.com/BSX ]

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. It offers implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities and implantable pacemaker systems used to manage slow or irregular heart rhythms.

Earlier this week the company announced that it received a positive ruling in a patent infringement case with Johnson & Johnson involving stents used for heart patients. Johnson & Johnson had alleged that Boston Scientific's use of a drug on a drug-eluting stent infringed two patents.

Five Star Equities releases regular market updates on the Medical Equipment & Supplies industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.fivestarequities.com ] and get exclusive access to our numerous stock reports and industry newsletters.

Antares Pharma, Inc., a pharmaceutical company, focuses on self-injection pharmaceutical products and technologies, and topical gel-based products. Earlier this month the company announced that it has licensed exclusively its Oxybutynin Gel 3% to Daewoong Pharmaceuticals Co. Ltd.,for marketing in South Korea. Antares oxybutynin gel 3% is a topical, translucent hydroalcoholic gel containing oxybutynin, an antispasmodic, antimuscarinic agent.

Last month Antares licensed to Pfizer Inc.'s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
[ www.fivestarequities.com/disclaimer ]